Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by SVB Leerink

SVB Leerink assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $5.00 price objective on the biopharmaceutical company’s stock.

LXRX has been the subject of a number of other reports. Needham & Company LLC restated a hold rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 23rd. StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a research note on Monday, April 15th.

Lexicon Pharmaceuticals Stock Performance

LXRX stock opened at $1.74 on Tuesday. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07. The firm has a market cap of $428.46 million, a P/E ratio of -2.17 and a beta of 1.38. Lexicon Pharmaceuticals has a 12-month low of $0.92 and a 12-month high of $3.79. The stock’s 50 day simple moving average is $2.12 and its 200 day simple moving average is $1.74.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. As a group, equities research analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LXRX. BVF Inc. IL grew its stake in shares of Lexicon Pharmaceuticals by 22.2% in the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after purchasing an additional 4,440,300 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Lexicon Pharmaceuticals in the third quarter worth $64,000. KWB Wealth bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth $62,000. RPO LLC bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth $49,000. Finally, TIAA Trust National Association bought a new position in shares of Lexicon Pharmaceuticals in the third quarter worth $29,000. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.